Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026287 | 0.90 | AGTR1 (0.57) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL1025210 | 0.88 | AGTR1 (0.46) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL1026476 | 0.88 | RAB9A (0.51) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL1026088 | 0.80 | NPC1 (0.56) | RAB9ANPC1MAPTAGTR1NCOA1 | |
| SCHEMBL1028098 | 0.79 | AGTR1 (0.74) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL2485773 | 0.71 | KMT2A (0.75) | RAB9ANPC1MAPTGAATLR7 | |
| SCHEMBL29571462 | 0.71 | KMT2A (0.75) | RAB9ANPC1MAPTGAATLR7 | |
| SCHEMBL12720802 | 0.68 | AGTR1 (0.71) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL1028452 | 0.68 | AGTR1 (0.91) | RAB9ANPC1MAPTGAAAGTR1 | |
| SCHEMBL12955841 | 0.67 | AGTR1 (0.60) | RAB9ANPC1MAPTGAAAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | claimed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | claimed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | claimed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | claimed |
| EP-2945629-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | ONCOCHEL THERAPEUTICS LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | Oncochel Therapeutics LLC (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2014078898-A1 | CHEMOTHERAPY FOR DRUG-RESISTANT CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | disclosed |
| EP-1608623-B1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | RICHARDSON DESI RAYMOND (AU) | 2011-01-19 | — | — | EP | disclosed |
| EP-1608623-A4 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | RICHARDSON, DESI (AU) | 2006-11-09 | — | — | US | disclosed |
| EP-1608623-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004069801-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306081-A1 | Chemotherapy for Drug-Resistant Cancer Cells | ABCC1, SLC47A1, ABCB1 | RAB9A 1746/4885NPC1 201/4885MAPT 4232/4885 |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | SLC40A1, SLC30A6, SLC39A3 | RAB9A 3737/4885NPC1 886/4885MAPT 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.